1BIIB:BIT
Biogen Inc
€198.78
arrow_downward
-1.13%(-2.27) 1D
Oct 2, 5:26:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
News stories
From web sources and news partners
Investing.com
·
1 hour ago
Biogen stock hits 52-week high at $241.00
Stock Traders Daily
·
16 hours ago
(BIIB) Movement as an Input in Quant Signal Sets
ad-hoc-news.de
·
2 days ago
JPMorgan lifts target for Biogen stock to USD 300.00
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia